SNSE Sensei Biotherapeutics, Inc.
Price Chart
Executive Summary
Sensei Biotherapeutics filed Amendment No. 1 to its 2025 Form 10-K solely to revise Part I Item 1 (Business) in response to SEC staff comments. The amendment expands disclosure around the February 2026 acquisition of Faeth Therapeutics (including its lead asset PIKTOR), the $200M private placement, clinical trial details, and competitive landscape. No financial statements were amended, no restatements were made, and the original financial data remains unchanged.
Actionable Insight
The 10-K/A is purely a disclosure enhancement, not a financial event — no stock-moving catalyst. Monitor Phase 2 endometrial cancer topline data at year-end 2026 and interim Phase 1b breast cancer data in 2027 for meaningful catalysts. Competitive risk from Celcuity's gedatolisib PDUFA date of July 17, 2026 warrants attention.
Key Facts
- Amendment filed solely to revise Business section (Item 1) in response to SEC staff comments
- No financial statements, restatements, or auditor changes were made
- Original 10-K filed March 30, 2026; amendment filed June 2, 2026
- Revised Section 302 certifications (Exhibits 31.3, 31.4) filed with paragraphs 3-5 omitted since no financial or control changes
- Acquisition of Faeth Therapeutics closed February 17, 2026, bringing PIKTOR (oral PI3K/AKT/mTOR inhibitor) into pipeline
- Received $200M gross proceeds from private placement to fund PIKTOR development
- Phase 2 endometrial cancer trial (FTH-PIK-201) topline data expected year-end 2026
- Phase 1b HR+/HER2- breast cancer trial (FTH-PIK-101) first patient dosed May 2026
- Patent portfolio for PIKTOR includes 13 issued U.S. patents with expiration between 2027-2046
- Takeda milestone obligations: up to $119M development/regulatory milestones + up to $250M sales milestones for PIKTOR
Financial Impact
No financial restatement or revision. Filing is administrative — expands business description and pipeline disclosure only.
Risk Factors
- Direct competition from gedatolisib (Celcuity) with FDA decision expected July 17, 2026, and other PI3K/AKT/mTOR candidates in development
- Clinical trial execution risk — PIKTOR data readouts for endometrial (year-end 2026) and breast cancer (2027) may disappoint
- Reliance on Takeda-licensed assets with milestone obligations ($119M + $250M) creating significant future cash commitments if successful
- Pre-revenue clinical-stage biotech with $27M market cap and history of restructuring (65% workforce reduction in Nov 2025)
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-K/A Filing (Primary) | 0001193125-26-252637 |
| Document: d130328dex313.htm | 0001193125-26-252637 |
| Document: d130328dex314.htm | 0001193125-26-252637 |
| Document: 0001193125-26-252637-index-headers.html | 0001193125-26-252637 |
| Document: 0001193125-26-252637-index.html | 0001193125-26-252637 |
| Document: 0001193125-26-252637.txt | 0001193125-26-252637 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 10, 2026
2d ago
|
S-3/A
| $11.26 awaiting T+1 | awaiting T+1 | — | $13.00 (+15.45%) |
|
Jun 10, 2026
2d ago
|
8-K
| $11.26 awaiting T+1 | awaiting T+1 | — | $13.00 (+15.45%) |
|
Jun 2, 2026
10d ago
|
10-K/A
| $16.10 $15.85 | ▼ −1.55% | ▼ −0.86% | $13.00 (−19.23%) |
|
Jun 2, 2026
10d ago
|
S-3/A
| $16.10 $15.85 | ▲ +1.55% | ▲ +0.86% | $13.00 (+19.23%) |
|
Jun 1, 2026
11d ago
|
Insider Cluster
| $16.10 $15.85 | ▲ +1.55% | ▲ +0.83% | $13.00 (+19.23%) |
|
May 22, 2026
21d ago
|
DEFA14A
| $16.47 $15.84 | ▼ −3.83% | ▼ −3.78% | $13.00 (−21.07%) |
|
May 22, 2026
21d ago
|
8-K
| $16.47 $15.84 | ▼ −3.83% | ▼ −3.78% | $13.00 (−21.07%) |
|
May 21, 2026
22d ago
|
DEFA14A
| $17.79 $16.47 | ▼ −7.42% | ▼ −8.01% | $13.00 (−26.93%) |
|
May 15, 2026
28d ago
|
8-K
| $20.43 $19.91 | ▼ −2.55% | ▼ −2.48% | $13.00 (−36.37%) |
|
Apr 29, 2026
6w ago
|
144
| $28.30 $26.62 | ▲ +5.94% | ▲ +6.96% | $13.00 (+54.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access